Sort
48,018 grants matching “immunotherapy”
Trinity: Transcriptome assembly for genetic and functional analysis of cancer
$587,235Brian Haas · Broad Institute, Inc. · U24 · FY2022 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
$587,169Xiaoguang Margaret Liu · Ohio State University · R01 · FY2023 · CA
TrialNet: Diabetes Type 1 Prevention
$587,158Peter A Gottlieb · University Of Colorado Denver · U01 · FY2016 · DK
TrialNet: Diabetes Type 1 Prevention
$587,158Peter A Gottlieb · University Of Colorado Denver · U01 · FY2015 · DK
TrialNet: Diabetes Type 1 Prevention
$587,157Peter A Gottlieb · University Of Colorado Denver · U01 · FY2017 · DK
Increasing the efficacy of non-activated CAR T cells by modulating IFN1 signaling
$587,108Saba Ghassemi · University Of Pennsylvania · R01 · FY2024 · CA
Increasing the efficacy of non-activated CAR T cells by modulating IFN1 signaling
$587,108Saba Ghassemi · University Of Pennsylvania · R01 · FY2025 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$587,093John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Regulatory T Cell Function in Ovarian Cancer
$587,055Kirsten B Moysich · Roswell Park Cancer Institute Corp · R01 · FY2012 · CA
Induction of effector lymphocyte lethargy by helminth coinfection
$587,042George S. Yap · Rbhs-New Jersey Medical School · R01 · FY2021 · AI
Induction of effector lymphocyte lethargy by helminth coinfection
$587,042George S. Yap · Rbhs-New Jersey Medical School · R01 · FY2019 · AI
Induction of effector lymphocyte lethargy by helminth coinfection
$587,042George S. Yap · Rbhs-New Jersey Medical School · R01 · FY2020 · AI
Induction of effector lymphocyte lethargy by helminth coinfection
$587,042George S. Yap · Rbhs-New Jersey Medical School · R01 · FY2017 · AI
Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
$587,031Arlene H Sharpe · University Of Pittsburgh At Pittsburgh · P01 · FY2015 · AI
Immune injury as a driver for the development of ascending aortic aneurysms and dissections
$587,029Zhihua Jiang · University Of Florida · R01 · FY2021 · HL
Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model
$587,012Ryan C Fields · Washington University · R01 · FY2023 · CA
Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model
$587,011Ryan C Fields · Washington University · R01 · FY2022 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$587,009Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2024 · CA
Rapamycin and IL-21 Conditioned CD8+ T Cells for Adoptive Cellular Therapy of Ov
$586,921Protul Shrikant · Roswell Park Cancer Institute Corp · P50 · FY2014 · CA
ChAT, AChE, and Cholinergic Neurons in Aging and AD
$586,906Steven G Younkin · Mayo Clinic Jacksonville · R01 · FY2009 · AG
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
$586,828Michael John Evans · University Of California, San Francisco · R01 · FY2019 · EB
Phase 0-1 Clinical Trials
$586,813James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
$586,680Sandi Alexander Kwee · Queen'S Medical Center · R01 · FY2023 · CA
TARGETED PRO-INFLAMMATORY PRODRUGS FOR THE IMMUNOTHERAPY OF KIDNEY CANCER
$586,655The University Of Texas Southwestern Medical Center · · FY2019 · Defense Health Agency
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$586,358Alejandro V Villagra · George Washington University · R01 · FY2021 · CA